PD-1, gender, and autoimmunity

Autoimmunity Reviews

Volumn 9, Issue 8, 2010, Pages 583-587

  Dinesh, Ravi K ^a   Hahn, Bevra H ^a   Singh, Ram Pyare ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmunity; Gender; Immune system; PD 1; Sex hormones; Systemic lupus erythematosus

Indexed keywords

ESTRADIOL; ESTROGEN; G PROTEIN COUPLED RECEPTOR 30; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; PROLACTIN;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNITY; BREAST CANCER; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; ESOPHAGUS CANCER; GRAFT VERSUS HOST REACTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFECTION; KIDNEY CARCINOMA; LYMPHOCYTIC CHORIOMENINGITIS; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; STOMACH CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; AUTOIMMUNITY; FEMALE; GONADAL STEROID HORMONES; HUMANS; IMMUNE TOLERANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 77952742119     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.04.003     Document Type: Review

References (90)

1. Ishida Y., Agata Y., Shibahara K., and Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J 11 (1992) 3887-3895
2. Okazaki T., and Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27 (2006) 195-201
3. Nishimura H., Agata Y., Kawasaki A., Sato M., Imamura S., Minato N., et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol 8 (1996) 773-780
4. Yamazaki T., Akiba H., Iwai H., Matsuda H., Aoki M., Tanno Y., et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169 (2002) 5538-5545
5. Ansari M.J., Salama A.D., Chitnis T., Smith R.N., Yagita H., Akiba H., et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198 (2003) 63-69
6. Iwai Y., Terawaki S., Ikegawa M., Okazaki T., and Honjo T. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 198 (2003) 39-50
7. Liang S.C., Latchman Y.E., Buhlmann J.E., Tomczak M.F., Horwitz B.H., Freeman G.J., et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 33 (2003) 2706-2716
8. Salama A.D., Chitnis T., Imitola J., Ansari M.J., Akiba H., Tushima F., et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 198 (2003) 71-78
9. Wiendl H., Mitsdoerffer M., Schneider D., Chen L., Lochmuller H., Melms A., et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. Faseb J 17 (2003) 1892-1894
10. Keir M.E., Butte M.J., Freeman G.J., and Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008) 677-704
11. Ishida M., Iwai Y., Tanaka Y., Okazaki T., Freeman G.J., Minato N., et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett 84 (2002) 57-62
12. Zhong X., Tumang J.R., Gao W., Bai C., and Rothstein T.L. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur J Immunol 37 (2007) 2405-2410
13. Keir M.E., Liang S.C., Guleria I., Latchman Y.E., Qipo A., Albacker L.A., et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203 (2006) 883-895
14. Dong C., Nurieva R.I., and Prasad D.V. Immune regulation by novel costimulatory molecules. Immunol Res 28 (2003) 39-48
15. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu Rev Immunol 23 (2005) 515-548
16. Okazaki T., Maeda A., Nishimura H., Kurosaki T., and Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 98 (2001) 13866-13871
17. Sharpe A.H., Wherry E.J., Ahmed R., and Freeman G.J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8 (2007) 239-245
18. Carter L., Fouser L.A., Jussif J., Fitz L., Deng B., Wood C.R., et al. PD-1: PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 32 (2002) 634-643
19. Chemnitz J.M., Parry R.V., Nichols K.E., June C.H., and Riley J.L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173 (2004) 945-954
20. Nurieva R., Thomas S., Nguyen T., Martin-Orozco N., Wang Y., Kaja M.K., et al. T-cell tolerance or function is determined by combinatorial costimulatory signals. Embo J 25 (2006) 2623-2633
21. Dong H., Zhu G., Tamada K., and Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5 (1999) 1365-1369
22. + T cell activation. Eur J Immunol 36 (2006) 2472-2482
23. Van Keulen V.P., Ciric B., Radhakrishnan S., Heckman K.L., Mitsunaga Y., Iijima K., et al. Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12. Clin Exp Immunol 143 (2006) 314-321
24. Nishimura H., Minato N., Nakano T., and Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 10 (1998) 1563-1572
25. Nishimura H., Nose M., Hiai H., Minato N., and Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11 (1999) 141-151
26. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291 (2001) 319-322
27. Mazanet M.M., and Hughes C.C. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169 (2002) 3581-3588
28. Blazar B.R., Carreno B.M., Panoskaltsis-Mortari A., Carter L., Iwai Y., Yagita H., et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 171 (2003) 1272-1277
29. Latchman Y.E., Liang S.C., Wu Y., Chernova T., Sobel R.A., Klemm M., et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 101 (2004) 10691-10696
30. + T cells and relieves the lupus-like nephritis of NZB/W F1 mice. J Immunol 184: 2337-47.
31. Wang J., Yoshida T., Nakaki F., Hiai H., Okazaki T., and Honjo T. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A 102 (2005) 11823-11828
32. + T-cell mediated injury in the heart. Circulation 116 (2007) 2062-2071
33. Cheng X., Zhao Z., Ventura E., Gran B., Shindler K.S., and Rostami A. The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma. J Neuroimmunol 185 (2007) 75-86
34. Magnus T., Schreiner B., Korn T., Jack C., Guo H., Antel J., et al. Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci 25 (2005) 2537-2546
35. Zhu B., Guleria I., Khosroshahi A., Chitnis T., Imitola J., Azuma M., et al. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol 176 (2006) 3480-3489
36. Carter L.L., Leach M.W., Azoitei M.L., Cui J., Pelker J.W., Jussif J., et al. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 182 (2007) 124-134
37. Kroner A., Mehling M., Hemmer B., Rieckmann P., Toyka K.V., Maurer M., et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 58 (2005) 50-57
38. Nielsen C., Hansen D., Husby S., Jacobsen B.B., and Lillevang S.T. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62 (2003) 492-497
39. Kong E.K., Prokunina-Olsson L., Wong W.H., Lau C.S., Chan T.M., Alarcon-Riquelme M., et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 52 (2005) 1058-1062
40. Prokunina L., Castillejo-Lopez C., Oberg F., Gunnarsson I., Berg L., Magnusson V., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32 (2002) 666-669
41. Prokunina L., Padyukov L., Bennet A., de Faire U., Wiman B., Prince J., et al. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 50 (2004) 1770-1773
42. Prokunina L., Gunnarsson I., Sturfelt G., Truedsson L., Seligman V.A., Olson J.L., et al. The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum 50 (2004) 327-328
43. Lin S.C., Yen J.H., Tsai J.J., Tsai W.C., Ou T.T., Liu H.W., et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 50 (2004) 770-775
44. Johansson M., Arlestig L., Moller B., and Rantapaa-Dahlqvist S. Association of a PDCD1 polymorphism with renal manifestations in systemic lupus erythematosus. Arthritis Rheum 52 (2005) 1665-1669
45. Wang S.C., Chen Y.J., Ou T.T., Wu C.C., Tsai W.C., Liu H.W., et al. Programmed death-1 gene polymorphisms in patients with systemic lupus erythematosus in Taiwan. J Clin Immunol 26 (2006) 506-511
46. Lee S.H., Lee Y.A., Woo D.H., Song R., Park E.K., Ryu M.H., et al. Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res Ther 8 (2006) R163
47. + Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 119 (2009) 551-564
48. + regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp 252 (2003) 67-88 (discussion -91, 106-14)
49. + regulatory T cells. Proc Natl Acad Sci U S A 105 (2008) 9331-9336
50. + T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol 180 (2008) 2069-2080
51. + regulatory T cell induced by ICOS-B7h blockade in vivo. J Immunol 179 (2007) 786-796
52. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006) 682-687
53. Trabattoni D., Saresella M., Biasin M., Boasso A., Piacentini L., Ferrante P., et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 101 (2003) 2514-2520
54. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 (2006) 350-354
55. + T cell survival in HIV infection. J Exp Med 203 (2006) 2281-2292
56. + T cells leads to reversible immune dysfunction. Nat Med 12 (2006) 1198-1202
57. Urbani S., Amadei B., Tola D., Massari M., Schivazappa S., Missale G., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 80 (2006) 11398-11403
58. + T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 80 (2006) 3532-3540
59. Das S., Suarez G., Beswick E.J., Sierra J.C., Graham D.Y., and Reyes V.E. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol 176 (2006) 3000-3009
60. Cohen N., Morisset J., and Emilie D. Induction of tolerance by Porphyromonas gingivalis on APCS: a mechanism implicated in periodontal infection. J Dent Res 83 (2004) 429-433
61. + T cells. J Immunol 177 (2006) 4021-4027
62. Liang S.C., Greenwald R.J., Latchman Y.E., Rosas L., Satoskar A., Freeman G.J., et al. PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur J Immunol 36 (2006) 58-64
63. Freeman G.J., Wherry E.J., Ahmed R., and Sharpe A.H. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 203 (2006) 2223-2227
64. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (2002) 793-800
65. + T cells. Cancer Res 64 (2004) 1140-1145
66. Brown J.A., Dorfman D.M., Ma F.R., Sullivan E.L., Munoz O., Wood C.R., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170 (2003) 1257-1266
67. Wintterle S., Schreiner B., Mitsdoerffer M., Schneider D., Chen L., Meyermann R., et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63 (2003) 7462-7467
68. Ohigashi Y., Sho M., Yamada Y., Tsurui Y., Hamada K., Ikeda N., et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11 (2005) 2947-2953
69. Wu C., Zhu Y., Jiang J., Zhao J., Zhang X.G., and Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108 (2006) 19-24
70. Ghebeh H., Mohammed S., Al-Omair A., Qattan A., Lehe C., Al-Qudaihi G., et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8 (2006) 190-198
71. Thompson R.H., Kuntz S.M., Leibovich B.C., Dong H., Lohse C.M., Webster W.S., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66 (2006) 3381-3385
72. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., and Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99 (2002) 12293-12297
73. Dong H., and Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 81 (2003) 281-287
74. Zandman-Goddard G., Peeva E., and Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev 6 (2007) 366-372
75. Yacoub Wasef S.Z. Gender differences in systemic lupus erythematosus. Gend Med 1 (2004) 12-17
76. Grimaldi C.M., Hill L., Xu X., Peeva E., and Diamond B. Hormonal modulation of B cell development and repertoire selection. Mol Immunol 42 (2005) 811-820
77. Roubinian J.R., Talal N., Greenspan J.S., Goodman J.R., and Siiteri P.K. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 147 (1978) 1568-1583
78. Lahita R.G., and Bradlow H.L. Klinefelter's syndrome: hormone metabolism in hypogonadal males with systemic lupus erythematosus. J Rheumatol Suppl 14 Suppl 13 (1987) 154-157
79. Sthoeger Z.M., Zinger H., and Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 62 (2003) 341-346
80. Peeva E., Venkatesh J., and Diamond B. Tamoxifen blocks estrogen-induced B cell maturation but not survival. J Immunol 175 (2005) 1415-1423
81. Apelgren L.D., Bailey D.L., Fouts R.L., Short L., Bryan N., Evans G.F., et al. The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice. Cell Immunol 173 (1996) 55-63
82. Peeva E., Grimaldi C., Spatz L., and Diamond B. Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest 106 (2000) 1373-1379
83. Walker S.E. Bromocriptine treatment of systemic lupus erythematosus. Lupus 10 (2001) 762-768
84. + regulatory T cell compartment. J Immunol 173 (2004) 2227-2230
85. Polanczyk M.J., Hopke C., Huan J., Vandenbark A.A., and Offner H. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J Neuroimmunol 170 (2005) 85-92
86. Polanczyk M.J., Hopke C., Vandenbark A.A., and Offner H. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res 84 (2006) 370-378
87. Wang C., Dehghani B., Li Y., Kaler L.J., Vandenbark A.A., and Offner H. Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology 126 (2009) 329-335
88. Polanczyk M.J., Hopke C., Vandenbark A.A., and Offner H. Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol 19 (2007) 337-343
89. Wang C., Dehghani B., Li Y., Kaler L.J., Proctor T., Vandenbark A.A., et al. Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J Immunol 182 (2009) 3294-3303
90. Polanczyk M.J., Jones R.E., Subramanian S., Afentoulis M., Rich C., Zakroczymski M., et al. T lymphocytes do not directly mediate the protective effect of estrogen on experimental autoimmune encephalomyelitis. Am J Pathol 165 (2004) 2069-2077